1
|
Ljubicic L, Janzic U, Unk M, Terglav AS, Mohorcic K, Seiwerth F, Bitar L, Badovinac S, Plestina S, Korsic M, Kukulj S, Samarzija M, Jakopovic M. Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis. Radiol Oncol 2023; 57:397-404. [PMID: 37665737 PMCID: PMC10476899 DOI: 10.2478/raon-2023-0040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Accepted: 07/16/2023] [Indexed: 09/06/2023] Open
Abstract
BACKGROUND The standard first-line systemic treatment for patients with non-oncogene addicted advanced nonsquamous non-small cell lung cancer (NSCLC) is immunotherapy with immune checkpoint inhibitors (ICI) and/or chemotherapy (ChT). Therapy after failing ICI +/- ChT remains an open question, and docetaxel plus nintedanib represent a valid second line option. PATIENTS AND METHODS A multicenter retrospective trial of real-life treatment patterns and outcomes of patients with advanced lung adenocarcinoma treated with docetaxel plus nintedanib after the failure of ICI and/or ChT was performed. Patients from 2 Slovenian and 1 Croatian oncological center treated between June 2014 and August 2022 were enrolled. We assessed objective response (ORR), disease control rate (DCR), median progression free survival (PFS), median overall survival (OS), and safety profile of treatment. RESULTS There were 96 patients included in the analysis, with ORR of 18.8%, DCR of 57.3%, median PFS of 3.0 months (95% CI: 3.0-5.0 months), and a median OS of 8.0 months (95% CI: 7.0-10.0 months). The majority of patients (n = 47,49%) received docetaxel plus nintedanib as third-line therapy. The ORR for this subset of patients was 19.1%, with a DCR of 57.4%. The highest response rate was observed in patients who received second-line docetaxel plus nintedanib after first-line combination of ChT-ICI therapy (n = 24), with an ORR of 29.2% and DCR of 66.7% and median PFS of 4.0 months (95% CI: 3.0-8.0 months). Fifty-three patients (55.2%) experienced adverse events (AEs), most frequently gastrointestinal; diarrhea (n = 29, 30.2%), and increased liver enzyme levels (n = 17, 17.7%). CONCLUSIONS The combination of docetaxel and nintedanib can be considered an effective therapy option with an acceptable toxicity profile for patients with advanced NSCLC after the failure of ICI +/- ChT.
Collapse
Affiliation(s)
- Lidija Ljubicic
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Urska Janzic
- Medical Oncology Unit, University Clinic Golnik, Golnik, Slovenia
- Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | - Mojca Unk
- Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | - Ana Sophie Terglav
- Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | - Katja Mohorcic
- Medical Oncology Unit, University Clinic Golnik, Golnik, Slovenia
| | - Fran Seiwerth
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Lela Bitar
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Sonja Badovinac
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
- School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Sanja Plestina
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
- School of Medicine, University of Rijeka, Rijeka, Croatia
| | - Marta Korsic
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
- School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Suzana Kukulj
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
- School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Miroslav Samarzija
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
- School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Marko Jakopovic
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
- School of Medicine, University of Zagreb, Zagreb, Croatia
| |
Collapse
|
2
|
Seiwerth F, Bitar L, Franolić IL, Šajnić A, Jakopović M, Samaržija M. EP08.02-058 A Case Series of Patients With Kras KRAS G12C Mutation Treated With Sotorasib - Croatian Experience. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.740] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Jakopovic M, Seiwerth F, Bitar L, Ljubicic L, Maletic O, Karabatic S, Samarzija M. EP07.01-012 Ipilimumab and Nivolumab in Pretreated Patients with Malignant Pleural Mesothelioma. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
4
|
Seiwerth F, Bitar L, Krpina K, Markelić I, Glodić G, Džubur F, Smojver Ježek S, Mataić A, Samaržija M, Jakopović M. P40.13 Lung Cancer 5-Year Survival in Croatia - Our Experience. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Bitar L, Seiwerth F, Ljubičić L, Bačelić-Gabelica A, Srdić D, Koršić M, Badovinac S, Pleština S, Samaržija M, Jakopović M. Survival outcomes of patients diagnosed with lung adenocarcinoma with ALK gene rearrangement. Lung Cancer 2021. [DOI: 10.1183/13993003.congress-2021.pa2312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
6
|
Srdic D, Bitar L, Seiwerth F, Gabaj NN, Marusic A, Vuletic LB, Badovinac S, Plestina S, Samarzija M, Jakopovic M. 1323P Immunotherapy for PDL1-high (TPS≥50%) metastatic NSCLC: Results in real-world oncology practice. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Vincelj J, Bitar L. Quality of life 10 years after cardiac surgery in adults: a long-term follow-up study. Health Qual Life Outcomes 2020; 18:382. [PMID: 33302953 PMCID: PMC7730735 DOI: 10.1186/s12955-020-01642-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Accepted: 12/07/2020] [Indexed: 11/10/2022] Open
Abstract
We have read the article titled "Quality of life 10 years after cardiac surgery in adults: a long-term follow-up study " by Perrotti A. et al. published in your distinguished journal with great interest. Unfortunately, we found few errors in this article.
Collapse
Affiliation(s)
- Josip Vincelj
- Faculty of Medicine Osijek, University Josip Juraj Strossmayer Osijek, Josipa Huttlera 4, 31000, Osijek, Croatia. .,Polyclinic for Cardiology "BOGDAN", Bužanova 4, 10000, Zagreb, Croatia.
| | - Lela Bitar
- Department for Pulmonary Diseases, University Hospital Center Zagreb, Jordanovac 104, 10000, Zagreb, Croatia
| |
Collapse
|
8
|
Abstract
Thymic epithelial tumors (TETs) are rare thymic neoplasms. There are approximately 1.5 cases per million TETs per year. They are the most common anterior mediastinal tumors in adults. Due to limited activity of available treatment options novel strategies and treatment options are needed and treatment with immune checkpoint inhibitors is an attractive option. Thymic epithelial tumors have one of the lowest tumor mutational burden among all cancer in adults, but high expression of PD-L1 on tumor cells and abundant CD8+ lymphocytes provide a strong rational for implementing immune checkpoint inhibitors (ICIs) which target PD-1/PD-L1 pathway in the treatment of TETs. Few small early stage clinical trials were published so far evaluating efficacy of pembrolizumab and avelumab in thymoma and thymic carcinoma patients. Al trials showed reasonable response rates and progression-free survival. Higher PD-L1 expression was predictor of response in all trials. However, increased incidence of immune-related adverse events was seen in TET patients treated with immune checkpoint inhibitors compared to patients with other cancers. At the moment, ICIs are not standard of care for patients with TET and larger trials are needed to establish the right role of ICIs regarding efficacy and safety of these agents.
Collapse
Affiliation(s)
- Marko Jakopovic
- School of Medicine, University of Zagreb, Zagreb, Croatia.,Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Lela Bitar
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Fran Seiwerth
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Ante Marusic
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Kristina Krpina
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Miroslav Samarzija
- School of Medicine, University of Zagreb, Zagreb, Croatia.,Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| |
Collapse
|
9
|
JAKOPOVIC MARKO, Bitar L, Krpina K, Seiwerth F, Marusic A, Plestina S, Kukulj S, Roglic M, Korsic M, Badovinac S, Samarzija M. Atezolizumab and platinum-based chemotherapy in extensive-stage small cell lung cancer: A single center experience. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.e21110] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21110 Background: In extensive stage small-cell lung cancer (ES-SCLC) immune check-point inhibitors, atezolizumab and durvalumab, when combined with chemotherapy in the first-line setting show better efficacy than chemotherapy alone with safety profile similar as the adverse events of individual agents. Methods: We administered atezolizumab, etoposide and platinum, either carboplatin or cisplatin, in the first-line treatment in 24 newly diagnosed patients with ES-SCLC. Patients were treated until disease progression or unacceptable toxicity. Results: Out of 24 treated patients 13 were males and 11 were females, median age 61 (ranging from 44 to 80). Majority of patients were ECOG 1. Median number of atezolizumab doses was 8 (ranging from 2 to 11). We observed median progression free survival of 6 months (95%CI 4,28-7,72), while median overall survival was not reached. 10 patients (41%) are still undergoing treatment and 9 patients (37%) have died. Immune-related adverse events occurred in 6 patients (25%). Four patients developed pneumonitis (all of them CTCAE grade 2), two patients colitis (CTCAE grade 2 and 3) and one patient rash, CTCAE grade 3. Median treatment pause was 5 weeks (ranging from 3 to 12 weeks). There were no treatment discontinuations due to adverse events nor treatment related deaths. Conclusions: Atezolizumab combined with chemotherapy in ES-SCLC showed good tolerability and effectiveness in real world setting. Our data are consistent with published clinical trial data. There was no new safety signal in our patient cohort. Limitations of our report are small sample size and short follow-up time.
Collapse
Affiliation(s)
| | - Lela Bitar
- Univeristy Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | - Ante Marusic
- University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | | | - Marta Korsic
- University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | |
Collapse
|
10
|
Badovinac S, Roglić M, Korsic M, Bitar L, Jakopovic M, Smojver-Ježek S, Samarzija M. P2.05-18 Tissue Sampling and Prognostic Biomarkers Analysis of Peripheral Lung Tumors Using R-EBUS. Single Centre Retrospective Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
11
|
Bitar L, Seiwerth F, Srdić D, Bačelić-Gabelica A, Pleština S, Samaržija M, Jakopovic M. P3.01-08 Gender Differences in Lung Cancer Survival. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Krpina K, Kukulj S, Budimir B, Drpa G, Bitar L, Seiwerth F, Čuk B, Marušić A, Grah JJ, Jakopović M, Samaržija M. Limited role of Ki-67 in lung carcinoid tumor patients predicting overall short-term survival, A single institution experience. Lung Cancer 2018. [DOI: 10.1183/13993003.congress-2018.pa2782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
13
|
Jakopovic M, Bitar L, Cucevic B, Plestina S, Mazuranic I, Seiwerth S, Hecimovic A, Vukic Dugac A, Jankovic M, Redzepi G, Samarzija M. First experience with osimertinib in patients with T790M mutation previously treated with EGFR – TKIs in Croatia. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e20518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20518 Background: EGFR T790M mutation is responsible for around 60% cases of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in patients who have lung cancer with an activating EGFR mutation. Methods: We administered osimertinib 80 mg once daily in 8 patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with first and second-line EGFR tyrosine kinase inhibitors. Results: We treated 8 patients with osimertinib with stage IV lung adenocarcinoma. Four patients were males and four were females, median age 62 (raging from 54 to 82). Four patients were never smoker, and four were ex-smokers. All patients had initially deletion 19 in EGFR gene and then developed T790M mutation. In all patients T790M was proven from tumor tissue. Majority of patients were ECOG 1. All patients were previously treated with first or second line EGFR TKIs (erlotinib, gefitinib or afatinib) and had radiologically documented disease progression. Three patients were treated with osimertinib in third line setting, 2 in fourth, one in fifth, one in sixth and one even in tenth line setting. Median time to response was 4 weeks (raging from 3 to 7). All 8 patients had partial response (PR) with still no recorded disease progression. Duration of response is from 7 to 46 weeks and still ongoing. No significant side effects were observed. Conclusions: Osimertinib is highly active in patients with lung adenocarcinoma which harbor EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. There were no serious side effects of treatment.
Collapse
Affiliation(s)
| | - Lela Bitar
- Univeristy Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | | | | | | | | | | | - Gzim Redzepi
- University Hospital Centre Zagreb, Zagreb, Croatia
| | | |
Collapse
|
14
|
Bitar L, Seiwerth F, Markelić I, Koršić M, Pleština S, Čučević B, Kukulj S, Roglić M, Jakopović M, Samaržija M. P1.05-077 Outcome of N2 Disease in NSCLC - A Single Institution Experience. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Markelić I, Bitar L, Seiwerth F, Čučević B, Kukulj S, Plestina S, Dzubur F, Samarzija M, Jakopovic M. P2.02-051 Prognostic Value of the Pretreatment Peripheral Blood Markers in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.1198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Jakopovic M, Fedza D, Bitar L, Markelić I, Seiwerth F, Hecimovic A, Čučević B, Mazuranic I, Redzepi G, Dugic AV, Jankovic M, Samarzija M. P1.04-025 The Impact of Emergency Presentation on Survival of Lung Cancer Patients. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
17
|
Seiwerth F, Bitar L, Markelić I, Dzubur F, Brcic L, Seiwerth S, Misic M, Roglić M, Plestina S, Čučević B, Kukulj S, Smojver-Jezek S, Samarzija M, Jakopovic M. P3.02b-114 Second Line Treatment of EGFR Positive Lung Adenocarcinoma - Our Experience. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.1782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
Vincelj J, Barišin A, Bitar L, Jakšić Jurinjak S, Horvat D, Barišin S, Sonicki Z. PS154 Assessment of the Myocardial Performance Index in Patients With First Acute Myocardial Infarction. Glob Heart 2016. [DOI: 10.1016/j.gheart.2016.03.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
19
|
Jakopovic M, Bitar L, Markelic I, Seiwerth F, Dzubur F, Hecimovic A, Cucevic B, Mazuranic I, Redzepi G, Vukic Dugac A, Jankovic Makek M, Samarzija M. The effect of emergency presentation on survival of lung cancer patients. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e18041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Lela Bitar
- Univeristy Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | - Fedza Dzubur
- University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | | | - Gzim Redzepi
- University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | | |
Collapse
|
20
|
Vincelj J, Bitar L, Jendričko T, Udovičić M, Petrovečki M. Health-related quality of life five years after coronary artery bypass graft surgery. Int J Cardiol 2014; 182:68-9. [PMID: 25576722 DOI: 10.1016/j.ijcard.2014.12.106] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2014] [Accepted: 12/25/2014] [Indexed: 10/24/2022]
Affiliation(s)
- Josip Vincelj
- Institute of Cardiovascular Diseases, Dubrava University Hospital, Zagreb, Croatia; University of Applied Health Studies, Zagreb, Croatia.
| | - Lela Bitar
- Clinic for Pulmonary Diseases, University Hospital Center Zagreb, Zagreb, Croatia
| | - Tihana Jendričko
- Department of Psychiatry, University Psychiatric Hospital Vrapče, Zagreb, Croatia
| | - Mario Udovičić
- Institute of Cardiovascular Diseases, Dubrava University Hospital, Zagreb, Croatia
| | - Mladen Petrovečki
- Laboratory Diagnostics, Dubrava University Hospital, Zagreb, Croatia
| |
Collapse
|
21
|
Kristiansen NI, Stohl A, Prata AJ, Richter A, Eckhardt S, Seibert P, Hoffmann A, Ritter C, Bitar L, Duck TJ, Stebel K. Remote sensing and inverse transport modeling of the Kasatochi eruption sulfur dioxide cloud. ACTA ACUST UNITED AC 2010. [DOI: 10.1029/2009jd013286] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|